INDP · Indaptus Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Anderson Glen R. 10% Owner | ▲ Buy | Open Market | 1,190,400 Shares held | 8/14/2023 | View profile |
| Meckler Jeffrey A CEO and Director | ▲ Buy | Grant | 229,929 Shares held | 12/22/2025 | View profile |
| Newman Michael James CSO and Director | ▲ Buy | Grant | 101,074 Shares held | 12/22/2025 | View profile |
| Linscott Walt Addison Chief Business Officer | ▲ Buy | Grant | 54,426 Shares held | 12/22/2025 | View profile |
| Sassi Nir Chief Financial Officer | ▲ Buy | Grant | 26,758 Shares held | 12/22/2025 | View profile |
| Avraham Ben-Tzvi Director | ▲ Buy | Grant | 25,100 Shares held | 1/20/2026 | View profile |
| Litchev Boyan Vesselinov Chief Medical Officer | ▲ Buy | Open Market | 1,150 Shares held | 12/1/2022 | View profile |
Transaction History
| Avraham Ben-Tzvi | ▲ Buy | Grant | 25,000 | $0 | 1/20/2026 |
| Linscott Walt Addison | ▲ Buy | Grant | 54,421 | $110K | 12/22/2025 |
| Newman Michael James | ▲ Buy | Grant | 52,204 | $106K | 12/22/2025 |
| Meckler Jeffrey A | ▲ Buy | Grant | 216,617 | $440K | 12/22/2025 |
| Sassi Nir | ▲ Buy | Grant | 26,758 | $54K | 12/22/2025 |
| Meckler Jeffrey A | ▲ Buy | Grant | 6,068 | $50K | 7/27/2025 |
| Meckler Jeffrey A | ▲ Buy | Grant | 42,553 | $50K | 11/25/2024 |
| Meckler Jeffrey A | ▲ Buy | Grant | 84,932 | $155K | 8/8/2024 |
| Anderson Glen R. | ▲ Buy | Open Market | 23,934 | $56K | 8/14/2023 |
| Anderson Glen R. | ▲ Buy | Open Market | 35,064 | $74K | 8/11/2023 |
| Anderson Glen R. | ▲ Buy | Open Market | 44,354 | $86K | 8/10/2023 |
| Litchev Boyan Vesselinov | ▲ Buy | Open Market | 500 | $935 | 12/1/2022 |
| Litchev Boyan Vesselinov | ▲ Buy | Open Market | 500 | $915 | 11/22/2022 |
| Meckler Jeffrey A | ▲ Buy | Open Market | 9,600 | $18K | 11/21/2022 |
| Meckler Jeffrey A | ▲ Buy | Open Market | 400 | $705 | 11/18/2022 |
| Meckler Jeffrey A | ▲ Buy | Open Market | 10,308 | $29K | 9/8/2022 |
| Linscott Walt Addison | ▲ Buy | Open Market | 150 | $393 | 9/7/2022 |
| Meckler Jeffrey A | ▲ Buy | Open Market | 8,632 | $22K | 9/7/2022 |
| Meckler Jeffrey A | ▲ Buy | Open Market | 1,060 | $3K | 9/6/2022 |
| Meckler Jeffrey A | ▲ Buy | Open Market | 19,727 | $52K | 6/6/2022 |
| Litchev Boyan Vesselinov | ▲ Buy | Open Market | 50 | $205 | 3/2/2022 |
| Newman Michael James | ▼ Sell | Open Market | 14,130 | $71K | 2/1/2022 |
| Litchev Boyan Vesselinov | ▲ Buy | Open Market | 100 | $465 | 1/31/2022 |
| Newman Michael James | ▼ Sell | Open Market | 5,870 | $29K | 1/31/2022 |
| Meckler Jeffrey A | ▲ Buy | Open Market | 11,187 | $65K | 11/18/2021 |
| Meckler Jeffrey A | ▲ Buy | Open Market | 12,000 | $84K | 9/14/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Indaptus named among top small-cap healthcare performers
Indaptus Therapeutics was highlighted in a recent report as one of five smaller health care stocks that outperformed Moderna in September. The stock is currently trading near the upper end of its 52-week range, reflecting this recent strength. This inclusion in a performance-based list draws attention to the company's recent market activity relative to larger peers.
Indaptus named among top small-cap healthcare performers. Indaptus Therapeutics was highlighted in a recent report as one of five smaller health care stocks that outperformed Moderna in September. The stock is currently trading near the upper end of its 52-week range, reflecting this recent strength. This inclusion in a performance-based list draws attention to the company's recent market activity relative to larger peers.